EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma

K Korpinen, T A Autere, J Tuominen, E Löyttyniemi, N Eigeliene, K Talvinen, P Kronqvist

Breast Cancer Research and Treatment · 2025

DOI: 10.1007/s10549-024-07584-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2025. Verfasst von K Korpinen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10/MedD5A, 20500, Turku, Finland. kkhkor@utu.fi. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Suomen Lääketieteen Säätiö, University of Turku.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Due to biological heterogeneity of breast carcinoma, predicting the individual response to neoadjuvant treatment (NAT) is complex. Consequently, there are no comprehensive, generally accepted practices to guide post-treatment follow-up. We present clinical and histopathological criteria to advance the prediction of disease outcome in NA-treated breast cancer.

Methods

A retrospective consecutive cohort of 257 NA-treated Finnish breast cancer patients with up to 13-year follow-up and the corresponding tissue samples of pre- and post-NAT breast and metastatic specimen were evaluated for prognostic impacts. All relevant clinical and biomarker characteristics potentially correlated with tumor response to NAT, course of disease, or outcome of breast cancer were included in the statistical analyses.

Results

The results highlight the intensified characterization of distinguished prognostic factors and previously overlooked histological features, e.g., mitotic and apoptotic activity. Particularly, decreased PR indicated 3.8-fold (CI 1.9–7.4, p = 0.0001) mortality risk, and a > 10.5-year shorter survival for the majority, > 75% of patients (Q1). Clinically applicable prognostic factors both preceding and following NAT were identified and compiled into heat maps to quantify mortality and recurrence risks. Combinations of risk factors for aggressive disease were exemplified as an interactive tool (bcnatreccalc.utu.fi) to illustrate the spectrum of disease outcomes.

Conclusion

The results emphasize the value of comprehensive evaluation of conventional patient and biomarker characteristics, especially concerning re-assessment of biomarkers, risk-adapted surveillance, and personalized treatment strategies. Future personalized NA-treatment strategies might benefit from models combining risk-adapted surveillance data and post-NAT re-assessed biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleNeoadjuvant TherapyMiddle AgedRisk AssessmentAgedAdultPrognosisPrecision MedicineRetrospective StudiesBiomarkers, TumorTreatment OutcomeRisk Factors

Stichwörter der Autor:innen

BiomarkerBreast cancerNeoadjuvantPrognosisRisk evaluation

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10/MedD5A, 20500, Turku, Finland. kkhkor@utu.fi.
  • Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10/MedD5A, 20500, Turku, Finland.
  • Department of Pathology, Turku University Hospital, Turku, Finland.
  • Department of Biostatistics, University of Turku, Turku, Finland.
  • Department of Oncology, Vaasa Central Hospital, Vaasa, Finland.

Förderung

  • Suomen Lääketieteen Säätiö
  • University of Turku

Zitieren

APA

Korpinen, K., Autere, T. A., Tuominen, J., Löyttyniemi, E., Eigeliene, N., Talvinen, K., & Kronqvist, P. (2025). Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07584-4

Vancouver

Korpinen K, Autere TA, Tuominen J, Löyttyniemi E, Eigeliene N, Talvinen K, et al. Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma. Breast Cancer Research and Treatment. 2025. doi:10.1007/s10549-024-07584-4

BibTeX
@article{Korpinen2025,
  author = {Korpinen, K and Autere, T A and Tuominen, J and Löyttyniemi, E and Eigeliene, N and Talvinen, K and Kronqvist, P},
  title = {Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma},
  journal = {Breast Cancer Research and Treatment},
  year = {2025},
  doi = {10.1007/s10549-024-07584-4}
}
Kostenlos starten →